| Page 1404 | Kisaco Research
 

Shannon Altimari

Global Head of Oncology Advocacy to Outcomes
GSK

Shannon joined GSK in 2020 as the company’s Global Head of Oncology Advocacy to Outcomes. In this role, she leads GSK’s oncology patient advocacy strategies, with a focus on improving outcomes and supporting equitable access for patients. Prior to GSK, she was with TESARO Bio GmbH as Head of International Corporate Affairs. Before TESARO, she spent 10 years with Biogen. She is an American citizen currently living in Switzerland.

Shannon Altimari

Global Head of Oncology Advocacy to Outcomes
GSK

Shannon Altimari

Global Head of Oncology Advocacy to Outcomes
GSK

Shannon joined GSK in 2020 as the company’s Global Head of Oncology Advocacy to Outcomes. In this role, she leads GSK’s oncology patient advocacy strategies, with a focus on improving outcomes and supporting equitable access for patients. Prior to GSK, she was with TESARO Bio GmbH as Head of International Corporate Affairs. Before TESARO, she spent 10 years with Biogen. She is an American citizen currently living in Switzerland.

 

Shannon Altimari

Global Head of Oncology Advocacy to Outcomes
GSK

Shannon joined GSK in 2020 as the company’s Global Head of Oncology Advocacy to Outcomes. In this role, she leads GSK’s oncology patient advocacy strategies, with a focus on improving outcomes and supporting equitable access for patients. Prior to GSK, she was with TESARO Bio GmbH as Head of International Corporate Affairs. Before TESARO, she spent 10 years with Biogen. She is an American citizen currently living in Switzerland.

Shannon Altimari

Global Head of Oncology Advocacy to Outcomes
GSK

Shannon Altimari

Global Head of Oncology Advocacy to Outcomes
GSK

Shannon joined GSK in 2020 as the company’s Global Head of Oncology Advocacy to Outcomes. In this role, she leads GSK’s oncology patient advocacy strategies, with a focus on improving outcomes and supporting equitable access for patients. Prior to GSK, she was with TESARO Bio GmbH as Head of International Corporate Affairs. Before TESARO, she spent 10 years with Biogen. She is an American citizen currently living in Switzerland.

 
Livestock Supply Chain Connect 2023
20-21 Sep 2023
London, UK
Improve your production efficiency, sustainability and profitability through business-critical insights to overcome the biggest challenges facing our industry and counteract rising costs across Europe. Efficiently connect across your supply chain by meeting senior executives from across the meat, dairy and aquaculture supply chains across 2 days of prescheduled 1-2-1 meetings and interactive networking opportunities Discover the latest large scale, innovative solutions ready to be implemented across your supply chain at our executive panels and presentations from figureheads who are keen to connect to share their knowledge and solutions.  
Zama: Programmable Bootstrapping Enables Efficient Homomorphic Inference of Deep Neural Networks
 
AI Drug Discovery & Development Summit
18-20 Nov 2025
Boston, United States
 

Maria del Pilar Diaz Gonzalez

CEO at FemTech
MAS Holdings

Pilar is a global and multi-cultural business senior executive with 20+ years of experience in the consumer goods industry. She started her career in Spain where she is originally from, and later spanning multiple geographic locations across USA, Italy, Portugal, Switzerland and Germany. She built her career with a focus on Strategy, Marketing, Innovation and Commercialization.

Maria del Pilar Diaz Gonzalez

CEO at FemTech
MAS Holdings

Maria del Pilar Diaz Gonzalez

CEO at FemTech
MAS Holdings

Pilar is a global and multi-cultural business senior executive with 20+ years of experience in the consumer goods industry. She started her career in Spain where she is originally from, and later spanning multiple geographic locations across USA, Italy, Portugal, Switzerland and Germany. She built her career with a focus on Strategy, Marketing, Innovation and Commercialization. Pilar is currently the CEO at FemTech at MAS Holdings, the largest and leading design-to-delivery apparel solutions provider in South Asia. In her own words, she is "passionate about helping shape the future of FemHealth, an industry with massive growth potential that has been long neglected. Very proud to work with people who dare to break the taboos surrounding female intimate health and wellness, and support women through the ups and downs, the glory, and the pain, of every stage in their lives

 

Lauren Boas Hayes

Senior Advisor for Technology and Innovation
CISA

Lauren Boas Hayes

Senior Advisor for Technology and Innovation
CISA

Lauren Boas Hayes

Senior Advisor for Technology and Innovation
CISA
 

Dr Rand Hindi

Co-Founder and CEO
Zama

Dr Rand Hindi is an entrepreneur and deeptech investor. He is the CEO at Zama, an open source homomorphic encryption company, and an investor in 30+ companies across privacy, AI, blockchain, medtech and psychedelics. Rand started coding at the age of 10, founded a Social Network at 14 and a web agency at 15 before getting into Machine Learning at 18 and starting a PhD at 21. He then created Snips, the first edge-based, private by design voice solution for OEMs, which was then acquired by Sonos.

Dr Rand Hindi

Co-Founder and CEO
Zama

Dr Rand Hindi

Co-Founder and CEO
Zama

Dr Rand Hindi is an entrepreneur and deeptech investor. He is the CEO at Zama, an open source homomorphic encryption company, and an investor in 30+ companies across privacy, AI, blockchain, medtech and psychedelics. Rand started coding at the age of 10, founded a Social Network at 14 and a web agency at 15 before getting into Machine Learning at 18 and starting a PhD at 21. He then created Snips, the first edge-based, private by design voice solution for OEMs, which was then acquired by Sonos. He has been elected as a TR35 by the MIT Technology Review, as a "30 under 30" by Forbes, is a lecturer at Sciences Po in Paris and an advisor to multiple companies. He was previously a member of the French Digital Council where he focused on AI and Privacy issues. He holds a BSc in Computer Science and a PhD in Bioinformatics from University College London (UCL), as well as two graduate degrees from Singularity University in Silicon Valley and THNK in Amsterdam.